Google Health alive... and well? (Morning Read)

Highlights of the important and interesting in the world of healthcare:

Google Health alive… and well? Google Health seems to have been stuck in neutral almost from the start, Chilmark Research writes. But rumors of its death may be exaggerated, according to The Health Care Blog.

“Primary access” oversold? Dartmouth researchers found that having a greater supply of primary care physicians in a community doesn’t mean the community has better access to primary care. Does that mean the American College of Physicians and others who argue that primary care is positively associated with better outcomes, access and lower costs have had it all wrong?

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

While you were on vacation… Another antibiotic-resistant bacteria reached America’s shores, this one from India: New Delhi metallo-beta-lactamase NDM-1, according to HealthDay.

Prometheus v. Mayo. This case is one of several pending Federal Circuit appeals that questions whether medical diagnostic and treatment methods are the proper subject of patent protection, writes the Patently-O blog.

For me? Thank you! A new study offers a clue to why some doctors accept freebies: they believe the treats are a reward for the sacrifices made to study medicine, according to the Pharmalot blog.

More false drug marketing. The maker of antidepressant Celexa, a unit of Forest Laboratories, has agreed to pay more than $313 million to settle criminal and civil claims, including that it illegally promoted the drug for use in children, the New York Times reported.